We just need your registered Email Id
to sent your password reset
instructions.
You're doing something extraordinary. We'll keep you in the loop with our latest news and special offers. Please update your profile on a regular basis and be an active community member. Let others know we exist and together we can move medicine forward.
You are now registered within Modern Trials network. If we receive patient inquires within your zip code we will let you know. Be on the look out for an E-Mail from our team.
| NCT Id | NCT04108013 |
|---|---|
| Title | A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC |
| Condition | Lung Cancer Stage II |
| StudyType | Interventional |
| Organization | Xuanwu Hospital, Beijing |
| Sponsor/Collaborators | Xuanwu Hospital, Beijing |
| Status | Not yet recruiting |
| Gender | All |
| AgeGroup | Adult Older Adult |
| Location (with distance) | |
| Description | This study is a randomized, controlled, open-label, prospective, single-center phase II clinical study. Target population is patients with stage II and IIIA resectable non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to evaluate the major pathologic response of SHR-1210 + carboplatin + paclitaxel-albumin in subjects with resectable non-small cell lung cancer. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. |
Your interest has been recorded and our team is working hard for you. We will contact you with further steps.